Atara Biotherapeutics, Inc. (ATRA) vs Telomir Pharmaceuticals, Inc. Common Stock (TELO)

A side-by-side comparison of Atara Biotherapeutics, Inc. and Telomir Pharmaceuticals, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Atara Biotherapeutics, Inc. logo
ATRA
Atara Biotherapeutics, Inc.
$88M
$9.75HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Telomir Pharmaceuticals, Inc. Common Stock logo
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$83M
$1.20HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ATRA vs TELO

growth of $100 · dividends reinvested · last 3y
ATRA -66.1% (-30.3%/yr)TELO -82.7% (-44.3%/yr)ATRA compounded faster over this window
50100150Start $10020252026$34$17
ATRA TELO

ATRA vs TELO: by the numbers

  • •ATRA is the larger company ($88M vs $83M market cap).
  • •Both run net losses; TELO's is the smaller (0.00% vs -269.42% net margin).

Metrics side by side

Valuation

MetricATRATELO
P/S ratio14.18N/A
P/B ratioN/A16.40

Profitability

MetricATRATELO
Gross margin82.44%0.00%
Operating margin29.69%0.00%
Net margin-269.42%0.00%
ROEN/A-116.74%
ROIC-100.35%-120.93%

Growth (annualized)

MetricATRATELO
Revenue CAGR (5Y)56.10%N/A
Total return CAGR (5Y)-53.60%N/A

Go deeper

Full ATRA analysisFull TELO analysisInteractive comparison tool

Dig into the metrics

Atara Biotherapeutics ROETelomir Pharmaceuticals, Inc. Common Stock ROEAtara Biotherapeutics operating marginTelomir Pharmaceuticals, Inc. Common Stock operating marginAtara Biotherapeutics revenue growthTelomir Pharmaceuticals, Inc. Common Stock revenue growthAtara Biotherapeutics free cash flowTelomir Pharmaceuticals, Inc. Common Stock free cash flow

Atara Biotherapeutics & Telomir Pharmaceuticals, Inc. Common Stock appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.